1. Application of anti-DFS70 antibody and specific autoantibody test algorithms to patients with the dense fine speckled pattern on HEp-2 cells.
- Author
-
Lee H, Kim Y, Han K, and Oh EJ
- Subjects
- Autoantibodies immunology, Cell Line, Tumor, Connective Tissue Diseases diagnosis, Dermatomyositis diagnosis, Dermatomyositis immunology, Enzyme-Linked Immunosorbent Assay, Humans, Immunoassay, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic immunology, Mixed Connective Tissue Disease diagnosis, Mixed Connective Tissue Disease immunology, Rheumatic Diseases diagnosis, Rheumatic Diseases immunology, Scleroderma, Systemic diagnosis, Scleroderma, Systemic immunology, Sensitivity and Specificity, Sjogren's Syndrome diagnosis, Adaptor Proteins, Signal Transducing immunology, Algorithms, Antibodies, Antinuclear immunology, Connective Tissue Diseases immunology, Fluorescent Antibody Technique, Indirect methods, Sjogren's Syndrome immunology, Transcription Factors immunology
- Abstract
Objectives: Whereas antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) have diagnostic significance, the dense fine speckled (DFS) pattern on HEp-2 cells may be an exclusionary marker for ANA-associated rheumatic disease (AARD). The aim of this study was to evaluate a new algorithm considering anti-DFS70 antibodies for routine ANA testing., Method: From ANA requested sequential 10 528 sera, 181 sera samples showing the DFS pattern were additionally tested for anti-DFS70 antibodies by an enzyme-linked immunosorbent assay (ELISA-DFS70) and for specific-ANAs. Specific-ANAs(+)/IIF-DFS(-) control sera samples (n = 50) were also tested., Results: Of the 181 IIF-DFS-positive sera samples, 82.9% (n = 150) were from non-AARD patients and 112 (61.9%) patients had non-rheumatic diseases (NRD), including the most common clinical feature of dermatitis (18.2%). The ELISA-DFS70 was positive in 109 (60.2%) sera and was negative in all control sera. Specific-ANAs were similarly detected as 25.7% (28/109) and 22.2% (16/72) of ELISA-DFS70(+) and ELISA-DFS70(+) patients, respectively (p > 0.05). The prevalence of non-AARD was 95.1% and 25.1% in the ELISA-DFS70(+)/specific-ANAs(-) and ELISA-DFS70(-)/specific-ANAs (+) groups, respectively., Conclusions: In patients with a HEp-2 DFS pattern, the additional ELISA-DFS70 and specific-ANAs test could improve the efficiency of diagnosing AARD. The detection of anti-DFS70 antibodies should be included in test algorithms for ANA testing.
- Published
- 2016
- Full Text
- View/download PDF